Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Monday morning, Marketbeat reports. The brokerage issued a sell rating and a $80.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, FY2024 earnings at $2.30 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

Several other research analysts have also commented on the company. UBS Group raised their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Raymond James reissued an “outperform” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Price Performance

SRPT opened at $137.94 on Monday. Sarepta Therapeutics has a 52-week low of $78.67 and a 52-week high of $173.25. The company has a 50 day moving average of $121.90 and a two-hundred day moving average of $131.39. The company has a market cap of $13.18 billion, a P/E ratio of 104.40 and a beta of 0.81. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Activity at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SRPT. Tidal Investments LLC raised its position in shares of Sarepta Therapeutics by 8.5% during the first quarter. Tidal Investments LLC now owns 2,902 shares of the biotechnology company’s stock worth $376,000 after purchasing an additional 228 shares during the period. Castleark Management LLC purchased a new stake in Sarepta Therapeutics during the first quarter valued at about $304,000. Comerica Bank boosted its holdings in shares of Sarepta Therapeutics by 489.4% in the first quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock worth $432,000 after buying an additional 2,770 shares during the period. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics in the first quarter worth approximately $32,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after acquiring an additional 1,243,427 shares during the period. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.